Oxaprozinum [Inn-Latin] en es it fr

Oxaprozinum [Inn-Latin] Brand names, Oxaprozinum [Inn-Latin] Analogs

Oxaprozinum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Oxaprozinum [Inn-Latin] Chemical_Formula


Oxaprozinum [Inn-Latin] RX_link


Oxaprozinum [Inn-Latin] fda sheet

Oxaprozinum_[Inn-Latin] FDA

Oxaprozinum [Inn-Latin] msds (material safety sheet)

Oxaprozinum_[Inn-Latin] MSDS

Oxaprozinum [Inn-Latin] Synthesis Reference

No information avaliable

Oxaprozinum [Inn-Latin] Molecular Weight

293.317 g/mol

Oxaprozinum [Inn-Latin] Melting Point

158 - 159 oC

Oxaprozinum [Inn-Latin] H2O Solubility


Oxaprozinum [Inn-Latin] State


Oxaprozinum [Inn-Latin] LogP


Oxaprozinum [Inn-Latin] Dosage Forms


Oxaprozinum [Inn-Latin] Indication

Used to relieve the inflammation, swelling, stiffness, and joint pain associated with rheumatoid arthritis and osteoarthritis.

Oxaprozinum [Inn-Latin] Pharmacology

Oxaprozin is a nonsteroidal antiinflammatory drug (NSAID) with analgesic and antipyretic properties. Oxaprozin is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and to alleviate moderate pain.

Oxaprozinum [Inn-Latin] Absorption

Oxaprozin is 95% absorbed after oral administration. Food may reduce the rate of absorption of oxaprozin, but the extent of absorption is unchanged. Antacids do not significantly affect the extent and rate of oxaprozin absorption.

Oxaprozinum [Inn-Latin] side effects and Toxicity

Oral, mouse: LD50 = 1210 mg/kg; Oral, rabbit: LD50 = 172 mg/kg; Oral, rat: LD50 = 4470 mg/kg

Oxaprozinum [Inn-Latin] Patient Information

Daypro, like other drugs of its class, can cause discomfort and, rarely, more serious side effects, such as gastrointestinal bleeding, which may result in hospitalization and even fatal outcomes. Although serious gastrointestinal tract ulcerations and bleeding can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing any indicative sign or symptoms. Patients should be apprised of the importance of this follow-up.

Patients should report to their physicians the signs or symptoms of gastrointestinal ulceration or bleeding, skin rash, weight gain, or edema.

Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, jaundice, right upper quadrant tenderness, and “flu-like” symptoms). If these occur, patients should be instructed to stop therapy and seek immediate medical therapy.

Patients should also be instructed to seek immediate emergency help in the case of an anaphylactoid reaction.

In late pregnancy, as with other NSAIDs, Daypro should be avoided because it will cause premature closure of the ductus arteriosus.

Oxaprozinum [Inn-Latin] Organisms Affected

Humans and other mammals